Literature DB >> 12550739

Brain plasticity and pathology in psychiatric disease: sites of action for potential therapy.

Michael Spedding1, Isabelle Neau, Laszlo Harsing.   

Abstract

Recent advances have been made in understanding the changes in neuronal plasticity in psychiatric disease at the molecular level (changes in neurotransmission, long-term potentiation, long-term depression, glutamate receptors, synaptic strength and neurotrophic support) and the systems level (changes in hippocampal, frontal and amygdala function in health and disease and the impact of stress on the hippocampal/frontal axis), as well as in the impact of drugs and sites of action for therapeutic intervention. Drugs acting on plasticity could affect the abnormal set point in psychiatric disease, resulting in treatment of the disease rather than just the symptoms.

Entities:  

Mesh:

Year:  2003        PMID: 12550739     DOI: 10.1016/s1471-4892(02)00008-5

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  13 in total

Review 1.  AMPA receptors and synaptic plasticity: a chemist's perspective.

Authors:  James J Fleming; Pamela M England
Journal:  Nat Chem Biol       Date:  2010-02       Impact factor: 15.040

2.  Acute ketamine challenge increases resting state prefrontal-hippocampal connectivity in both humans and rats.

Authors:  Oliver Grimm; Natalia Gass; Wolfgang Weber-Fahr; Alexander Sartorius; Esther Schenker; Michael Spedding; Celine Risterucci; Janina Isabel Schweiger; Andreas Böhringer; Zhenxiang Zang; Heike Tost; Adam James Schwarz; Andreas Meyer-Lindenberg
Journal:  Psychopharmacology (Berl)       Date:  2015-07-18       Impact factor: 4.530

3.  Chronic escitalopram treatment restores spatial learning, monoamine levels, and hippocampal long-term potentiation in an animal model of depression.

Authors:  V Bhagya; B N Srikumar; T R Raju; B S Shankaranarayana Rao
Journal:  Psychopharmacology (Berl)       Date:  2010-11-04       Impact factor: 4.530

Review 4.  The anatomy of co-morbid neuropsychiatric disorders based on cortico-limbic synaptic interactions.

Authors:  S Totterdell
Journal:  Neurotox Res       Date:  2006-10       Impact factor: 3.911

Review 5.  Open questions in current models of antidepressant action.

Authors:  A Tanti; C Belzung
Journal:  Br J Pharmacol       Date:  2010-02-02       Impact factor: 8.739

Review 6.  Multistage drug effects of ketamine in the treatment of major depression.

Authors:  Martin Walter; Shijia Li; Liliana Ramona Demenescu
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-09-13       Impact factor: 5.270

Review 7.  Comorbidity implications in brain disease: neuronal substrates of symptom profiles.

Authors:  Tomas Palomo; Richard J Beninger; Richard M Kostrzewa; Trevor Archer
Journal:  Neurotox Res       Date:  2007-07       Impact factor: 3.911

Review 8.  Depression and antidepressants: molecular and cellular aspects.

Authors:  Cristina Lanni; Stefano Govoni; Adele Lucchelli; Cinzia Boselli
Journal:  Cell Mol Life Sci       Date:  2009-06-12       Impact factor: 9.261

9.  Protein SUMOylation modulates calcium influx and glutamate release from presynaptic terminals.

Authors:  Marco Feligioni; Atsushi Nishimune; Jeremy M Henley
Journal:  Eur J Neurosci       Date:  2009-04       Impact factor: 3.386

10.  Baseline effects of transcranial direct current stimulation on glutamatergic neurotransmission and large-scale network connectivity.

Authors:  Michael A Hunter; Brian A Coffman; Charles Gasparovic; Vince D Calhoun; Michael C Trumbo; Vincent P Clark
Journal:  Brain Res       Date:  2014-10-12       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.